Revvity Developing Automated Platform for Tuberculosis Testing
Revvity is developing the T-SPOT A201, an automated platform for latent tuberculosis testing in high-volume labs, with planned launch in 2027 pending regulatory approval.
Revvity is developing the T-SPOT A201, an automated platform for latent tuberculosis testing in high-volume labs, with planned launch in 2027 pending regulatory approval.
The NASHnext assay, powered by GENFIT's NIS4 technology, is designed to identify patients with at-risk MASH through a blood draw ordered via the Labcorp OnDemand platform.
The Atellica HEMA 580 is designed for mid- to high-volume labs to automate testing workflows and reduce preanalytical variability.
The patent covers a gene-expression profiling method designed to identify patients most likely to respond to the investigational therapy stenoparib through 2042.
Read MoreHerAnova Lifesciences presented validation data for HerResolve, a blood-based endometriosis test, showing 94.4% accuracy and detection of cases missed by imaging.
Read MoreCNSide Diagnostics has secured a national agreement with Elevance Health, expanding access to its CSF Tumor Cell Enumeration assay to 45.4 million more people in the US, Plus Therapeutics announced.
Read MoreGRAIL secured $110 million in equity financing from Samsung affiliates to support U.S. regulatory efforts and expand its Galleri multi-cancer early detection test into Asian markets, the companies announced.
Read MoreThe agreement combines extraction and PCR technologies to create an end-to-end workflow for DNA and RNA analysis.
Read MoreTecan has integrated agentic AI, powered by NVIDIA’s BioNeMo Agent Toolkit, into its Introspect laboratory analytics platform to enable proactive operations and improve productivity in clinical labs.
Read MoreThe approval allows Quest Diagnostics to offer its minimal residual disease test for patients in all 50 states.
Read MoreThe CIZ1B biomarker assay is designed to complement LDCT screening by helping assess lung cancer risk and clarify indeterminate findings.
Read MoreAgilent Technologies has partnered with OpenAI and Boston Consulting Group to accelerate artificial intelligence deployment in lab workflows, aiming to deliver faster scientific insights and advance intelligent instruments, software, and services.
Read MoreThe updated test includes additional DPYD variants recommended by the Association for Molecular Pathology to help identify patients who may be at risk for severe chemotherapy side effects.
Read MoreThe initiative aims to standardize digital pathology through an open-source platform and image management system.
Read MoreDiazyme Laboratories has acquired Carolina Liquid Chemistries, integrating CLC’s chemistry systems and reagents with Diazyme’s diagnostic technologies to expand solutions for reference and clinical laboratories.
Read MoreThe integrated electrophoresis solution is designed to simplify routine verification by eliminating gel casting and buffer preparation.
Read MoreThe Callisto Sample Prep System application is optimized for the PromethION platform to support whole genome sequencing workflows.
Read MoreThe new triple quadrupole mass spectrometry system aims to increase sample throughput and simplify interference removal.
Read More